Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panobinostat as Second-Line Therapy in Chronic Graft-Versus-Host Disease
NCT01028313Phase 2Withdrawn
- Sponsor
- SCRI Development Innovations
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in chronic graft-versus-host disease (cGVHD), sponsored by SCRI Development Innovations. Status: withdrawn.
02
Drugs
panobinostat
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT01028313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01028313.